NRG-DT001, Temporarily Closed to Accrual

CTEP has temporarily suspended accrual to NRG-DT001, “Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS),” effective immediately

The trial will reopen pending a CTEP-required amendment to reflect new biomarker information for TP53-wild type tumor status that is associated with eligibility, specimen collection, handling, and shipment elements.  NRG Oncology will send a broadcast when the trial reopens with the amended protocol.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse